一个混合可解释的人工智能框架 (HXAI) 用于对阿尔茨海默病的准确和可解释的诊断
Fatima Hasan Al-Bakri1, Wan Mohd Yaakob Wan Bejuri1,2, Mohamed Nasser Al-Andoli3
1Faculty of Information and Communication Technology, Universiti Teknikal Malaysia Melaka, Melaka 76100, Malaysia.
Diagnostics (Basel, Switzerland)
|December 30, 2025
概括
这项研究引入了用于阿尔茨海默病诊断的混合可解释AI (HXAI) 框架. 该HXAI框架结合了临床和MRI数据,提供双层解释性,以提高准确性和临床信任.
科学领域:
- 人工智能在医学中的应用
- 医学成像分析 医学成像分析
- 神经科学是一个神经科学.
背景情况:
- 可解释性AI (XAI) 对于临床诊断至关重要,但目前的方法有限.
- 现有的XAI方法通常集中在临床数据或MRI上,或缺乏清晰度,降低了效用.
- 需要集成的XAI框架来提高诊断精度和信任.
研究的目的:
- 为阿尔茨海默病 (AD) 诊断提出一种新的混合可解释AI (HXAI) 框架.
- 为了实现双层解释性,整合模型不可知和模型特定的解释方法.
- 提高AI在诊断AD的准确性和临床实用性.
主要方法:
- 开发了一个HXAI框架,集成SHAP (模型不可知) 和Grad-CAM (模型特定) 解释方法.
- 结合了临床特征 (MMSE,nWBV,SES,年龄) 与MRI衍生的特征 (ResNet50).
- 利用集体学习与逻辑回归元模型进行综合诊断.
主要成果:
- 基于特征的解释通过基于删除的测试实现了83.61%的可解释性准确性.
- 对MRI预测的模型特定解释达到了58.16%的可解释性准确度.
- 双层方法在解释诊断预测方面表现强.
结论:
- 该HXAI框架提供了多种解释AD诊断方法的结构化整合.
- 双层解释性提高了透明度和可解释性准确性.
- 拟议的框架弥合了AI模型准确性和对AD诊断的临床信心之间的差距.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744


